• BioM Biotech Cluster Development reported T-CURX appointed Florian Schmid as chief financial officer to lead finance, operations, investor relations.
• Schmid most recently served as CFO of iOmx Therapeutics.
• He previously was CFO and an executive board member at Vivoryon Therapeutics.
• Earlier, he held a senior finance role at InflaRx, supporting the company’s U.S. initial public offering.
• Appointment aligns with plans to extend a USD 20.5 million Series A financing, accelerating non-viral ex vivo, in vivo CAR-T programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioM Biotech Cluster Development GmbH published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.